Oligometastatic Disease: After 27 Years, Where Are We?

Saturday, March 12, 2022

10:10 AM – 11:10 AM US EST

Location: Las Olas IV, V, VI

Speaker(s)

Steven J. Chmura, MD, PhD

Professor of Radiation and Cellular Oncology and Medical Oncology
University of Chicago Medicine
Chicago, IL, United States

Disclosure: Astellas Pharm (Individual(s) Involved: Spouse/Partner): Employment (full or part time); AstraZeneca (Individual(s) Involved: Self): Consultant/Advisory Board, Research Grant; Bristol-Myers Squibb (Individual(s) Involved: Self): Research Grant; genentec (Individual(s) Involved: Self): Consultant/Advisory Board; Takeda Pharma (Individual(s) Involved: Self): Grant/Research Support

PDF Slides

Participants should be aware of the following financial/non-financial relationships:

Steven J. Chmura, MD, PhD: Astellas Pharm (Individual(s) Involved: Spouse/Partner): Employment (full or part time); AstraZeneca (Individual(s) Involved: Self): Consultant/Advisory Board, Research Grant; Bristol-Myers Squibb (Individual(s) Involved: Self): Research Grant; genentec (Individual(s) Involved: Self): Consultant/Advisory Board; Takeda Pharma (Individual(s) Involved: Self): Grant/Research Support

Learning Objectives:

The rationale and evidence for the clinical state of limited metastatic disease.
To dessiminate results of the intial trials.
Ongoing Phase 3 efforts and expected outcomes.